Skip to Main Content

Author Details

Gail P Risbridger
Biomedicine Discovery Institute, Monash University
1981
264
54
PMIDPaper TitleJournal TitlePublished Year
36629386Advances in preclinical models of prostate cancer for research discovery.J Endocrinol2023
37660083Low-dose carboplatin modifies the tumor microenvironment to augment CAR T cell efficacy in human prostate cancer models.Nat Commun2023
37945903Characterizing prostate cancer risk through multi-ancestry genome-wide discovery of 187 novel risk variants.Nat Genet2023
36650259The future of patient-derived xenografts in prostate cancer research.Nat Rev Urol2023
34687792Hidden clues in prostate cancer - Lessons learned from clinical and pre-clinical approaches on diagnosis and risk stratification.Cancer Lett2022
35413990OCT1-target neural gene PFN2 promotes tumor growth in androgen receptor-negative prostate cancer.Sci Rep2022
36923279Potent Stimulation of the Androgen Receptor Instigates a Viral Mimicry Response in Prostate Cancer.Cancer Res Commun2022
35869742New approaches to targeting epigenetic regulation in prostate cancer.Curr Opin Urol2022
35158771Chimeric Antigen Receptor T-Cell Therapy in Metastatic Castrate-Resistant Prostate Cancer.Cancers (Basel)2022
35014786Colorimetric Detection of Extracellular Hydrogen Peroxide Using an Integrated Microfluidic Device.Anal Chem2022
34784097Neuroendocrine cells in prostate cancer correlate with poor outcomes: a systematic review and meta-analysis.BJU Int2022
33473200Publisher Correction: Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction.Nat Genet2021
33737570Oxytocin receptor antagonists as a novel pharmacological agent for reducing smooth muscle tone in the human prostate.Sci Rep2021
33620092Androgen receptor enhancer amplification in matched patient-derived xenografts of primary and castrate-resistant prostate cancer.J Pathol2021
33799802Mast Cell-Derived SAMD14 Is a Novel Regulator of the Human Prostate Tumor Microenvironment.Cancers (Basel)2021
34462519A humanized orthotopic tumor microenvironment alters the bone metastatic tropism of prostate cancer cells.Commun Biol2021
34413304The MURAL collection of prostate cancer patient-derived xenografts enables discovery through preclinical models of uro-oncology.Nat Commun2021
34413130CX-5461 Sensitizes DNA Damage Repair-proficient Castrate-resistant Prostate Cancer to PARP Inhibition.Mol Cancer Ther2021
34111999High-Throughput Imaging Assay for Drug Screening of 3D Prostate Cancer Organoids.SLAS Discov2021
33406413Post-transcriptional Gene Regulation by MicroRNA-194 Promotes Neuroendocrine Transdifferentiation in Prostate Cancer.Cell Rep2021
33398198Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction.Nat Genet2021
32132214Knowing what's growing: Why ductal and intraductal prostate cancer matter.Sci Transl Med2020
33134178Recent Discoveries in the Androgen Receptor Pathway in Castration-Resistant Prostate Cancer.Front Oncol2020
33094211PDX: Moving Beyond Drug Screening to Versatile Models for Research Discovery.J Endocr Soc2020
32571390Comprehensive evaluation of targeted multiplex bisulphite PCR sequencing for validation of DNA methylation biomarker panels.Clin Epigenetics2020
32696317Parity reduces mammary repopulating activity but does not affect mammary stem cells defined as CD24â¿¿+â¿¿CD29/CD49fhi in mice.Breast Cancer Res Treat2020
32666799High-Aspect-Ratio SU-8-Based Optofluidic Device for Ammonia Detection in Cell Culture Media.ACS Sens2020
32188493Alterations in the methylome of the stromal tumour microenvironment signal the presence and severity of prostate cancer.Clin Epigenetics2020
32357309CRISP3 expression drives prostate cancer invasion and progression.Endocr Relat Cancer2020
32460015Combined TP53 and RB1 Loss Promotes Prostate Cancer Resistance to a Spectrum of Therapeutics and Confers Vulnerability to Replication Stress.Cell Rep2020
30622367Author Correction: Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci.Nat Genet2019
31556460Translational offsetting as a mode of estrogen receptor α-dependent regulation of gene expression.EMBO J2019
31212368Establishing a cryopreservation protocol for patient-derived xenografts of prostate cancer.Prostate2019
31520742A loss of estrogen signaling in the aromatase deficient mouse penis results in mild hypospadias.Differentiation2019
31225966A critical role for estrogen signaling in penis development.FASEB J2019
30808988The influence of BRCA2 mutation on localized prostate cancer.Nat Rev Urol2019
31061140Proteomic Profiling of Human Prostate Cancer-associated Fibroblasts (CAF) Reveals LOXL2-dependent Regulation of the Tumor Microenvironment.Mol Cell Proteomics2019
30728288Suppressing fatty acid uptake has therapeutic effects in preclinical models of prostate cancer.Sci Transl Med2019
30901730Characterization of the ERG-regulated Kinome in Prostate Cancer Identifies TNIK as a Potential Therapeutic Target.Neoplasia2019
29089445Novel imaging of the prostate reveals spontaneous gland contraction and excretory duct quiescence together with different drug effects.FASEB J2018
29892050Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants.Nat Commun2018
29892016Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci.Nat Genet2018
30049486Patient-derived Models of Abiraterone- and Enzalutamide-resistant Prostate Cancer Reveal Sensitivity to Ribosome-directed Therapy.Eur Urol2018
30073676Movember GAP1 PDX project: An international collection of serially transplantable prostate cancer patient-derived xenograft (PDX) models.Prostate2018
30428629Humanization of the Prostate Microenvironment Reduces Homing of PC3 Prostate Cancer Cells to Human Tissue-Engineered Bone.Cancers (Basel)2018
29636363Estrogen receptor subtypes dictate the proliferative nature of the mammary gland.J Endocrinol2018
29731970Elevated seminal plasma estradiol and epigenetic inactivation of <i>ESR1</i> and <i>ESR2</i> is associated with CP/CPPS.Oncotarget2018
29650553Enduring epigenetic landmarks define the cancer microenvironment.Genome Res2018
29311126Preclinical Models of Prostate Cancer: Patient-Derived Xenografts, Organoids, and Other Explant Models.Cold Spring Harb Perspect Med2018
29207252Role of activin C in normal ovaries and granulosa cell tumours of mice and humans.Reprod Fertil Dev2018
  • 1 - 50 of 264

Recommended Authors

Douglas W Strand
University of Texas Southwestern Medical Center
Career Start Year 2008
Number of shared co-authors 4
Brian W Simons
Center for Comparative Medicine, Baylor College of Medicine
Career Start Year 2008
Number of shared co-authors 2
Andrew S Goldstein
University of California los angeles
Career Start Year 2008
Number of shared co-authors 3
Antonio Hurtado-Coll
University of British Columbia
Career Start Year 2002
Number of shared co-authors 47
Ladan Fazli
University of British Columbia
Career Start Year 2002
Number of shared co-authors 26
Jiaoti Huang
Duke University School of Medicine
Career Start Year 2000
Number of shared co-authors 12
Eleonora Scarlata
Research Institute of the McGill University Health Center (RI-MUHC)
Career Start Year 1999
Number of shared co-authors 5
Elahe A Mostaghel
University of Washington
Career Start Year 1998
Number of shared co-authors 14
Isla P Garraway
David Geffen School of Medicine University of California Los Angeles
Career Start Year 1993
Number of shared co-authors 9
Marshall Scott Lucia
University of Colorado School of Medicine
Career Start Year 1991
Number of shared co-authors 9
Madeleine Moussa
Schulich School of Medicine and Dentistry, University of Western Ontario
Career Start Year 1989
Number of shared co-authors 5
Christopher P Evans
University of California Davis
Career Start Year 1988
Number of shared co-authors 27
Adrie van Bokhoven
University of Colorado Anschutz Medical Campus
Career Start Year 1988
Number of shared co-authors 3
Martin E Gleave
University of British Columbia
Career Start Year 1987
Number of shared co-authors 40
Anders Bjartell
Skane University Hospital, Lund University
Career Start Year 1987
Number of shared co-authors 27
Michael R Freeman
Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center
Career Start Year 1987
Number of shared co-authors 9
Eric P Smith
University of Cincinnati College of Medicine
Career Start Year 1986
Number of shared co-authors 0
Dean A Troyer
Eastern Virginia Medical School
Career Start Year 1985
Number of shared co-authors 9
Stephen Fawell
Oncology R&D
Career Start Year 1984
Number of shared co-authors 1
Massimo Loda
Weill Medical College of Cornell University
Career Start Year 1984
Number of shared co-authors 33
Kenneth J Pienta
The Brady Urological Institute, Johns Hopkins University School of Medicine
Career Start Year 1981
Number of shared co-authors 19
Steven P Balk
Beth Israel Deaconess Medical Center and Harvard Medical School
Career Start Year 1981
Number of shared co-authors 21
Philip W Kantoff
Memorial Sloan Kettering Cancer Center
Career Start Year 1981
Number of shared co-authors 43
Lawrence D True
University of Washington School of Medicine
Career Start Year 1980
Number of shared co-authors 17
Christopher S Foster
The Institute of Cancer Research
Career Start Year 1978
Number of shared co-authors 21
Simone Chevalier
McGill University Health Centre, McGill University
Career Start Year 1977
Number of shared co-authors 8
Ralph Buttyan
University of British Columbia
Career Start Year 1976
Number of shared co-authors 11
William E Grizzle
University of Alabama at Birmingham
Career Start Year 1974
Number of shared co-authors 3
Bernard Robaire
McGill University
Career Start Year 1973
Number of shared co-authors 0
Stephen R Plymate
University of Washington
Career Start Year 1973
Number of shared co-authors 20

Collaborators

Renea A Taylor
Peter MacCallum Cancer Centre
Co-authored papers 73
Mitchell G Lawrence
Biomedicine Discovery Institute, Monash University
Co-authored papers 38
Mark Frydenberg
Monash University
Co-authored papers 32
Judith A Clements
Co-authored papers 16
Melissa Papargiris
Biomedicine Discovery Institute, Monash University
Co-authored papers 15
David M Robertson
Co-authored papers 13
David Clouston
Co-authored papers 12
Declan G Murphy
Peter MacCallum Cancer Centre, University of Melbourne
Co-authored papers 10
Jeffrey B Kerr
Co-authored papers 9
Richard J Rebello
University of Melbourne
Co-authored papers 8
Ann E Drummond
Co-authored papers 7
Heather Thorne
Peter MacCallum Cancer Centre
Co-authored papers 7
Damien Bolton
University of Melbourne
Co-authored papers 7
Janet L Stanford
Fred Hutchinson Cancer Research Center
Co-authored papers 6
Stephen J Chanock
National Cancer Institute, National Institutes of Health
Co-authored papers 6
Monique J Roobol
Erasmus MC Cancer Institute, University Medical Center Rotterdam
Co-authored papers 6
Johanna Schleutker
Institute of Biomedicine, University of Turku
Co-authored papers 6
Stephanie J Weinstein
Co-authored papers 6
Sue A Ingles
Co-authored papers 6
Shannon K McDonnell
Mayo Clinic
Co-authored papers 6
Catharine M L West
University of Manchester
Co-authored papers 6
Børge G Nordestgaard
Co-authored papers 6
Demetrius Albanes
Co-authored papers 6
Gerald L Andriole
Co-authored papers 6
Christopher A Haiman
University of Southern California
Co-authored papers 6
David E Neal
University of Oxford, John Radcliffe Hospital
Co-authored papers 6
Kathryn L Penney
Co-authored papers 6
Elio Riboli
Co-authored papers 6
Zsofia Kote-Jarai
The Institute of Cancer Research
Co-authored papers 6
Cezary Cybulski
International Hereditary Cancer Center, Pomeranian Medical University
Co-authored papers 6
Release 1.2